Search Results | Diabetes | American Diabetes Association

1-6 of 6

Sort by

Sort Order Select

Meeting Abstracts

102-OR: Efficacy and Safety of Once-Weekly Efpeglenatide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (AMPLITUDE-M)

SEUNGJAE BAEK, JUAN P. FRIAS, LUIZA POPESCU, ELISABETH NIEMOELLER, ISABEL MUEHLEN-BARTMER, JULIO ROSENSTOCK

Diabetes 2021;70(Supplement_1):102-OR

DOI: https://doi.org/10.2337/db21-102-OR

Published: 01 June 2021

View article

Meeting Abstracts

149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)

LAWRENCE BLONDE, JULIO ROSENSTOCK, STEFANO DEL PRATO, ROBERT R. HENRY, NAIM SHEHADEH, ELISABETH NIEMOELLER, ELISABETH SOUHAMI, JUNLONG WU, XIANGLING WANG, CHEN JI, VANITA R. ARODA

Diabetes 2019;68(Supplement_1):149-OR

DOI: https://doi.org/10.2337/db19-149-OR

Published: 01 June 2019

View article

Meeting Abstracts

1139-P: Influence of Screening HbA_1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)

STEFANO DEL PRATO, LAWRENCE BLONDE, ROBERT R. HENRY, VANITA R. ARODA, NAIM SHEHADEH, ELISABETH NIEMOELLER, ELISABETH SOUHAMI, JUNLONG WU, XIANGLING WANG, CHEN JI, JULIO ROSENSTOCK

Diabetes 2019;68(Supplement_1):1139-P

DOI: https://doi.org/10.2337/db19-1139-P

Published: 01 June 2019

View article

Meeting Abstracts

1134-P: Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents

NEIL SKOLNIK, ELISABETH NIEMOELLER, ELISABETH SOUHAMI, LUIGI MENEGHINI

Diabetes 2019;68(Supplement_1):1134-P

DOI: https://doi.org/10.2337/db19-1134-P

Published: 01 June 2019

View article

Meeting Abstracts

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

JULIO ROSENSTOCK, LAWRENCE BLONDE, STEFANO DEL PRATO, ROBERT R. HENRY, NAIM SHEHADEH, ELISABETH NIEMOELLER, ELISABETH SOUHAMI, JUNLONG WU, XIANGLING WANG, CHEN JI, VANITA R. ARODA

Diabetes 2019;68(Supplement_1):1146-P

DOI: https://doi.org/10.2337/db19-1146-P

Published: 01 June 2019

View article

Meeting Abstracts

1032-P: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM

HIDEAKI KANETO, AKANE TAKAMI, ROBERT SPRANGER, ATSUSHI AMANO, DAISUKE WATANABE, ELISABETH NIEMOELLER

Diabetes 2019;68(Supplement_1):1032-P

DOI: https://doi.org/10.2337/db19-1032-P

Published: 01 June 2019

View article

NARROW

102-OR: Efficacy and Safety of Once-Weekly Efpeglenatide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (AMPLITUDE-M)

149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)

1139-P: Influence of Screening HbA_1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)

1134-P: Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

1032-P: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

102-OR: Efficacy and Safety of Once-Weekly Efpeglenatide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (AMPLITUDE-M)

149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)

1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)

1134-P: Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

1032-P: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only

1139-P: Influence of Screening HbA_1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)